Skip to main content
. 2020 Sep 21;11(11):2305–2311. doi: 10.1021/acsmedchemlett.0c00423

Figure 2.

Figure 2

TM-P2-Thal and TM-P4-Thal degrade SIRT2 selectively in cells. (A) Immunoblots for SIRT1, SIRT2, and SIRT3 after treating with indicated concentrations of inhibitors for 48 h in MCF7 and BT-549 cells. (B) Immunoblot for SIRT2 after MCF7 cells were treated with indicated concentrations of TM-P4-Thal for 48 h. (C) Immunoblot for SIRT2 after MCF7 cells were treated with 10 μM of TM-P4-Thal for the indicated incubation times.